Fig. 6: Neutralization of CD36 and CCL2 ameliorates NASH progression in Mettl3-HKO mice.

Mettl3-HKO mice at 8 weeks old were treated with a combination of anti-CD36 and anti-CCL2 antibodies (4 μg/antibody/mouse, i.v.) or an equal amount of control antibodies (IgA and IgG2b) on day 1, 4, 7, and 8 after MCD feeding. Mice were killed on day 9 after MCD feeding. a Serum ALT activity (n = 6 for each group; p = 0.0204). b Liver weights (n = 6 for each group; P = 0.0325). c Representative liver pictures. d Liver TAG levels (n = 6 for each group; P = 0.0108). e TUNEL-positive cells (n = 6 for each group; P = 0.0059). f The cleavage of caspase3 was measured by immunoblotting, quantified by ImageJ, and normalized to Tubulin (n = 4 for each group; P = 0.0043). The samples were derived from the same experiment and the blots were processed in parallel. n was the number of biologically independent mice. Data represent the mean ± SEM. Significance was determined by unpaired two-tailed Student’s t test analysis. *P < 0.05. **P < 0.01. Source data are provided as a Source Data file.